Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
대표청구항▼
1. An attenuated rhabdovirus comprising: an M protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4, orboth a G protein having an amino acid sequence that is at leas
1. An attenuated rhabdovirus comprising: an M protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4. 2. A method of killing a hyperproliferative cell comprising contacting the cell with an isolated oncolytic rhabdovirus encoding: an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4. 3. The method of claim 2, wherein the cell is comprised in a patient and the cell is a cancer cell. 4. The method of claim 3, wherein the cancer cell is a metastatic cancer cell. 5. The method of claim 2, wherein the cell is comprised in a patient and the oncolytic rhabdovirus is administered to the patient. 6. The method of claim 5, wherein the oncolytic rhabdovirus is administered by intraperitoneal, intravenous, intra-arterial, intramuscular, intradermal, intratumoral subcutaneous, or intranasal administration. 7. The method of claim 2, wherein contacting the cell with an isolated oncolytic rhabdovirus is a first anti-cancer therapy, and the method further comprises administering a second anti-cancer therapy. 8. The method of claim 7, wherein the second anti-cancer therapy is a second oncolytic virus. 9. The method of claim 8, wherein the second oncolytic virus is a vaccinia, herpes, measles, Newcastle disease, adenovirus, alphavirus, parvovirus, or rhabdovirus. 10. The method of claim 9, wherein the second oncolytic virus is a second oncolytic rhabdovirus. 11. The method of claim 10, wherein the second oncolytic rhabdovirus is vesicular stomatitis virus (VSV), Carajas virus, Chandripura virus, Cocal virus, Isfahan virus, Piry virus, Vesicular stomatitis Alagoas virus, BeAn 157575 virus, Boteke virus, Calchaqui virus, Eel virus American, Gray Lodge virus, Jurona virus, Klamath virus, Kwatta virus, La Joya virus, Malpais Spring virus, Mount Elgon bat virus, Perinet virus, Tupaia virus, Farmington, Bahia Grande virus, Muir Springs virus, Reed Ranch virus, Hart Park virus, Flanders virus, Kamese virus, Mosqueiro virus, Mossuril virus, Barur virus, Fukuoka virus, Kern Canyon virus, Nkolbisson virus, Le Dantec virus, Keuraliba virus, Connecticut virus, New Minto virus, Sawgrass virus, Chaco virus, Sena Madureira virus, Timbo virus, Almpiwar virus, Aruac virus, Bangoran virus, Bimbo virus, Bivens Arm virus, Blue crab virus, Charleville virus, Coastal Plains virus, DakArK 7292 virus, Entamoeba virus, Garba virus, Gossas virus, Humpty Doo virus, Joinjakaka virus, Kannamangalam virus, Kolongo virus, Koolpinyah virus, Kotonkon virus, Landjia virus, Manitoba virus, Marco virus, Nasoule virus, Navarro virus, Ngaingan virus, Oak-Vale virus, Obodhiang virus, Oita virus, Ouango virus, Parry Creek virus, Rio Grande cichlid virus, Sandjimba virus, Sigma virus, Sripur virus, Sweetwater Branch virus, Tibrogargan virus, Xiburema virus, Yata virus, Rhode Island, Adelaide River virus, Berrimah virus, Kimberley virus, or Bovine ephemeral fever virus. 12. The method of claim 7, wherein the second cancer therapy is chemotherapeutic, radiotherapeutic, or immunotherapeutic. 13. A method for treating a cancer patient comprising administering an effective amount of an isolated oncolytic rhabdovirus encoding: an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4. 14. The method of claim 13, wherein the oncolytic rhabdovirus is administered intraperitoneal, intravenous, intra-arterial, intramuscular, intradermal, intratumoral, subcutaneous, or intranasal administration. 15. The method of claim 13, further comprising administering a second cancer therapy. 16. The method of claim 15, wherein the second anti-cancer therapy comprises a second oncolytic virus. 17. The method of claim 16, wherein the second oncolytic virus is a vaccinia, herpes, measles, Newcastle disease, adenovirus, or rhabdovirus. 18. The method of claim 17, wherein the second anti-cancer therapy comprises a second oncolytic rhabdovirus. 19. The method of claim 18, wherein the second rhabdovirus is vesicular stomatitis virus (VSV), Carajas virus, Chandripura virus, Cocal virus, Isfahan virus, Maraba virus, Piry virus, Vesicular stomatitis Alagoas virus, BeAn 157575 virus, Boteke virus, Calchaqui virus, Eel virus American, Gray Lodge virus, Jurona virus, Klamath virus, Kwatta virus, La Joya virus, Malpais Spring virus, Mount Elgon bat virus, Perinet virus, Tupaia virus, Farmington, Bahia Grande virus, Muir Springs virus, Reed Ranch virus, Hart Park virus, Flanders virus, Kamese virus, Mosqueiro virus, Mossuril virus, Barur virus, Fukuoka virus, Kern Canyon virus, Nkolbisson virus, Le Dantec virus, Keuraliba virus, Connecticut virus, New Minto virus, Sawgrass virus, Chaco virus, Sena Madureira virus, Timbo virus, Almpiwar virus, Aruac virus, Bangoran virus, Bimbo virus, Bivens Arm virus, Blue crab virus, Charleville virus, Coastal Plains virus, DakArK 7292 virus, Entamoeba virus, Garba virus, Gossas virus, Humpty Doo virus, Joinjakaka virus, Kannamangalam virus, Kolongo virus, Koolpinyah virus, Kotonkon virus, Landjia virus, Manitoba virus, Marco virus, Nasoule virus, Navarro virus, Ngaingan virus, Oak-Vale virus, Obodhiang virus, Oita virus, Ouango virus, Parry Creek virus, Rio Grande cichlid virus, Sandjimba virus, Sigma virus, Sripur virus, Sweetwater Branch virus, Tibrogargan virus, Xiburema virus, Yata virus, Rhode Island, Adelaide River virus, Berrimah virus, Kimberley virus, or Bovine ephemeral fever virus. 20. The method of claim 15, wherein the second cancer therapy is chemotherapy, radiotherapy, immunotherapy, or surgery. 21. A composition comprising an isolated oncolytic rhabdovirus having a nucleic acid segment encoding: an M protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 5 and an arginine at the position corresponding to position 242 of SEQ ID NO:5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO:4. 22. The composition of claim 21, further comprising a second oncolytic virus. 23. The composition of claim 22, wherein the second oncolytic virus is vaccinia virus, herpes virus, measles virus, Newcastle disease virus, adenovirus, or rhabdovirus. 24. The composition of claim 23 wherein the second oncolytic virus is a rhabdovirus. 25. The composition of claim 24, wherein the second rhabdovirus is Carajas virus, Chandripura virus, Cocal virus, Isfahan virus, Maraba virus, Piry virus, Vesicular stomatitis Alagoas virus, BeAn 157575 virus, Boteke virus, Calchaqui virus, Eel virus American, Gray Lodge virus, Jurona virus, Klamath virus, Kwatta virus, La Joya virus, Malpais Spring virus, Mount Elgon bat virus, Perinet virus, Tupaia virus, Farmington, Bahia Grande virus, Muir Springs virus, Reed Ranch virus, Hart Park virus, Flanders virus, Kamese virus, Mosqueiro virus, Mossuril virus, Barur virus, Fukuoka virus, Kern Canyon virus, Nkolbisson virus, Le Dantec virus, Keuraliba virus, Connecticut virus, New Minto virus, Sawgrass virus, Chaco virus, Sena Madureira virus, Timbo virus, Almpiwar virus, Aruac virus, Bangoran virus, Bimbo virus, Bivens Arm virus, Blue crab virus, Charleville virus, Coastal Plains virus, DakArK 7292 virus, Entamoeba virus, Garba virus, Gossas virus, Humpty Doo virus, Joinjakaka virus, Kannamangalam virus, Kolongo virus, Koolpinyah virus, Kotonkon virus, Landjia virus, Manitoba virus, Marco virus, Nasoule virus, Navarro virus, Ngaingan virus, Oak-Vale virus, Obodhiang virus, Oita virus, Ouango virus, Parry Creek virus, Rio Grande cichlid virus, Sandjimba virus, Sigma virus, Sripur virus, Sweetwater Branch virus, Tibrogargan virus, Xiburema virus, Yata virus, Rhode Island, Adelaide River virus, Berrimah virus, Kimberley virus, or Bovine ephemeral fever virus. 26. The composition of claim 21, wherein the composition is a pharmaceutically acceptable composition. 27. The composition of claim 26, further comprising a second anti-cancer agent. 28. The composition of claim 27, wherein the second anti-cancer agent is a chemotherapeutic, radiotherapeutic, or immunotherapeutic. 29. The rhabdovirus of claim 1, wherein the G protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5 except for an arginine at the position corresponding to position 242 of SEQ ID NO: 5, and wherein the M protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 4 except for a tryptophan at the position corresponding to position 123 of SEQ ID NO: 4. 30. The method of claim 2, wherein the G protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5 except for an arginine at the position corresponding to position 242 of SEQ ID NO: 5, and wherein the M protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 4 except for a tryptophan at the position corresponding to position 123 of SEQ ID NO: 4. 31. The method of claim 13, wherein the G protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5 except for an arginine at the position corresponding to position 242 of SEQ ID NO: 5, and wherein the M protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 4 except for a tryptophan at the position corresponding to position 123 of SEQ ID NO: 4. 32. The composition of claim 21, wherein the G protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5 except for an arginine at the position corresponding to position 242 of SEQ ID NO: 5, and wherein the M protein has an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 4 except for a tryptophan at the position corresponding to position 123 of SEQ ID NO: 4.
Lilley Stephen John,GBX ; Taylor Hugh Francis,GBX ; Theobald David Reginald,GBX ; Carlson Craig J. ; Rosen David I. ; Johnson Thomas R., Coupling device for medical injection system.
Glazer Alexander N. ; Mathies Richard A. ; Hung Su-Chun ; Ju Jingyue, Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Babon Jeff,AUX ; Youil Rima,AUX ; Stoerker Jay ; Huff Anne ; Cotton Richard G. H.,AUX, Detection of mismatches by resolvase cleavage using a magnetic bead support.
Brow Mary Ann D. ; Hall Jeff Steven Grotelueschen ; Lyamichev Victor ; Olive David Michael ; Prudent James Robert, Detection of nucleic acid sequences by invader-directed cleavage.
Nadeau James G. ; Pitner J. Bruce ; Schram James L. ; Linn C. Preston ; Vonk Glenn P. ; Walker G. Terrance, Detection of nucleic acids by fluorescence quenching.
Nadeau James G. ; Pitner J. Bruce ; Schram James L. ; Linn C. Preston ; Vonk Glenn P. ; Walker G. Terrance, Detection of nucleic acids by fluorescence quenching.
Whiteley Norman M. (San Carlos CA) Hunkapiller Michael W. (San Carlos CA) Glazer Alexander N. (Orinda CA), Detection of specific sequences in nucleic acids.
Sedlacek Hans-Harald,DEX ; Bosslet Klaus,DEX ; Muller Rolf,DEX, Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound.
Krzyzek Richard A. (Edina MN) Laursen Cheryl R. M. (St. Paul MN) Anderson Paul C. (Minneapolis MN), Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Nelson Norman Charles ; Woodhead James Stuart,GBX ; Weeks Ian,GBX ; Cheikh Azzouz Ben, Labeled hybridization assay probes useful for the detection and quantification of multiple nucleic acid sequences.
Cleuziat Philippe,FRX ; Guillou-Bonnici Francoise,FRX ; Mallet Francois,FRX ; Levasseur Pierre,FRX, Method for nucleic acid amplification by transcription using displacement, and reagents and kit therefor.
Mirzabekov Andrei Darievich,RUX ; Lysov Yuri Petrovich,RUX ; Dubley Svetlana A.,RUX, Method for performing site-specific affinity fractionation for use in DNA sequencing.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Wu Linxian ; Coombs Jana ; Malmstrom Sharon L. ; Glass Michael J., Methods and apparatus for preparing, amplifying, and discriminating multiple analytes.
Adams Thomas R. (No. Stonington CT) Chambers Sheryl A. (Groton CT) Daines Richard J. (Ledyard CT) Gordon-Kamm William J. (Stonington CT) Kausch Albert P. (Stonington CT) Lemaux Peggy G. (Mystic CT) M, Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof.
Heller Michael James ; O'Connell James Patrick ; Juncosa Robert David ; Sosnowski Ronald George ; Jackson Thomas Ratcliffe, Methods for hybridization analysis utilizing electrically controlled hybridization.
Chang Yin-Fu (Carrboro NC) Wong James R. (Milpitas CA) Itano Andrea (Berkley CA) Mejza Stephen J. (Union City CA) Walker Leslie (Littleton CO), Methods for stable transformation of wheat.
Sousa Rui ; Jendrisak Jerome J., Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside trip.
Mirzabekov Andrei Darievich,RUX ; Lysov Yuri Petrovich,RUX ; Shick Valentine Vladimirovich ; Dubiley Svetlana Alekseevna,RUX, Microchip method for the enrichment of specific DNA sequences.
Hase Tetsu,JPX ; Masubuchi Harumi,JPX, Nucleic acid detection by repetitive synthesis and degradation of a nucleotide on a nuclease resistant oligonucleotide.
Urdea Michael S. ; Horn Thomas ; Chang Chu-An ; Warner Brian ; Fultz Timothy J., Nucleic acid hybridization assays employing large comb-type branched polynucleotides.
Hollis Mark A. ; Ehrlich Daniel J. ; Murphy R. Allen ; Kosicki Bernard B. ; Rathman Dennis D. ; Mathews Richard H. ; Burke Barry E. ; Eggers Mitch D. ; Hogan Michael E. ; Varma Rajender Singh, Optical and electrical methods and apparatus for molecule detection.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Schilperoort Robbert A. (Vincent van Goghlaan 40 2343 RP Oegstgeest NLX) Krens Frans A. (Scheveningen NLX) Wullems George J. (Warmond NLX), Process for the in-vitro transformation of plant protoplasts with plasmid DNA.
Shuler Charles P. (Westlake Village CA) Kedes Lawrence H. (Los Angeles CA) Prigozy Theodore I. (Los Angeles CA), Producing a protein in a mammal by injection of a DNA-sequence into the tongue.
Feinstone Stephen M. (3021 Cathedral Ave. ; NW. Washington DC 20008) Wychowski Czeslaw (10500 Montrose Ave. #2 Bethesda MD 20814) Silver Jonathan E. (7516 Arrowood Rd. Bethesda MD 20817) Emerson Suza, Techniques for producing site-directed mutagenesis of cloned DNA.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.